Future oncology (London, England) · 2026
Significance of the HALP score in patients with primary liver cancer undergoing hepatectomy: a meta-analysis.
СтатьяМетаанализОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Min, Xu Kailin, Ye Jufeng
Аннотация
AIM: This meta-analysis systematically assesses assessment of the association between the preoperative Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score and the prognosis in patients with primary liver cancer undergoing hepatectomy.
METHODS: A comprehensive exploration was carried out in five different databases to identify relevant articles. Stata 18.0 was employed to compute the combined HRs and 95% CIs for evaluating the relationships with survival endpoints. The primary outcome was overall survival (OS); disease/recurrence-free survival (DFS/RFS) were secondary outcomes.
RESULTS: Ten studies involving 2968 patients were included. Nine studies assessed the relationship between HALP score and OS (HR = 1.76, 95% CI = 1.53-2.03). Six studies analyzed the correlation with DFS/RFS (HR = 1.51, 95% CI = 1.30-1.76). Subgroup analyses revealed that cutoff values and covariate adjustment were major sources of heterogeneity for DFS/RFS.
CONCLUSION: A low preoperative HALP score is a notable biomarker for poorer survival in patients diagnosed with primary liver cancer undergoing hepatectomy. Being easily detectable and cost-effective, the HALP score is a valuable addition to existing cancer prognosis assessment tools in clinical practice.
METHODS: A comprehensive exploration was carried out in five different databases to identify relevant articles. Stata 18.0 was employed to compute the combined HRs and 95% CIs for evaluating the relationships with survival endpoints. The primary outcome was overall survival (OS); disease/recurrence-free survival (DFS/RFS) were secondary outcomes.
RESULTS: Ten studies involving 2968 patients were included. Nine studies assessed the relationship between HALP score and OS (HR = 1.76, 95% CI = 1.53-2.03). Six studies analyzed the correlation with DFS/RFS (HR = 1.51, 95% CI = 1.30-1.76). Subgroup analyses revealed that cutoff values and covariate adjustment were major sources of heterogeneity for DFS/RFS.
CONCLUSION: A low preoperative HALP score is a notable biomarker for poorer survival in patients diagnosed with primary liver cancer undergoing hepatectomy. Being easily detectable and cost-effective, the HALP score is a valuable addition to existing cancer prognosis assessment tools in clinical practice.